Groowe Groowe / Newsroom / IMTX
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

IMTX News

Immatics N.V. Ordinary Shares

Immatics Announces Full Year 2025 Financial Results and Business Update

globenewswire.com
IMTX

Ionic Mineral Technologies Secures Major SITLA Land Expansion at Silicon Ridge, Confirms Large-Scale Mineral System Continuity

businesswire.com
IMTX

Elevar Therapeutics Names Dong-Gun Kim CEO as It Focuses on Post-NDA Commercialization Strategy

globenewswire.com
IMTX

Flare Therapeutics Appoints Stephen L. Eck, M.D., Ph.D., as Chief Medical Officer

globenewswire.com
MGNX IMTX LLY PFE

Insights Into the Booming Peptide Cancer Vaccines Market 2025-2031: Key Trends & Opportunities in Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Other Applications - ResearchAndMarkets.com

businesswire.com
IMTX

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

globenewswire.com
IMTX

Immatics Announces $125 Million Underwritten Offering

globenewswire.com
IMTX

Immatics Announces Third Quarter 2025 Financial Results and Business Update

globenewswire.com
IMTX

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

globenewswire.com
IMTX